赛诺菲报告了强的第一季度销售和收益,维持2026年的预期. Sanofi reports strong Q1 sales and earnings, maintaining 2026 guidance.

尽管净利略有下降, 但赛诺菲报告第一季度销售和收益强. Sanofi reported strong first-quarter sales and earnings, driven by key products like Dupixent, despite a slight dip in net income. 公司在计划的领导层转型中维持了2026年的预期. The company maintained its 2026 guidance amid a planned leadership transition.